TriangleAdenosine A2B Receptor Antagonist… (NCT05234307)
Adenosine A2B Receptor Antagonist PBF-1129 trial for Metastatic Lung Non-Small Cell Carcinoma (NCT05234307). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for non small cell lung cancer that has come back or spread, in adults who have no curative options and have already received standard chemotherapy and immunotherapy.
The idea: add a daily pill to immunotherapy. PBF 1129 is an adenosine A2B receptor antagonist taken by mouth once a day, together with nivolumab by infusion. Cycles repeat every 28 days.
This phase 1b trial plans 30 patients and studies side effects and the best dose. At Ohio State in Columbus, Dwight Owen leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.